from the February 2016 issue


Medigus is leading the transition from invasive gastric surgery procedures to less invasive, patient-friendly techniques through the development of minimally invasive endoscopic devices and procedures. The company's revolutionary MUSE™ System enables endoscopists to treat gastroesophageal reflux disease (GERD), a chronic disease with increasing global prevalence, by performing a fundoplication procedure through the mouth. Unlike current fundoplication procedures, the MUSE™ System does not require abdominal incisions, which may result in shorter post-procedure recovery. The MUSE™ System (previously known as SRS™ System for transoral fundoplication) has received FDA clearance and CE mark. Medigus is traded on the Nasdaq Capital Market and the TASE (Tel-Aviv Stock Exchange).

Reprinted from the Israel High-Tech & Investment Report February 2016

Click HERE to request further information.
Click HERE to go BACK.